Summary IL-2, in addition to its immunomodulating and antitumour properties, induces important systemic actions, including cardiovascular, neuroendocrine and metabolic effects. The present study was carried out to evaluate IL-2 effects on cholesterol metabolism. The study included 14 advanced cancer patients (renal carcinoma: ten; colon carcinoma: four), who received IL-2 subcutaneously at a dose of 1.8 x 106 IU ml-2 twice daily for 5 days/week for 6 weeks. Venous blood samples were collected 7 days before, on days 0, 3, 7, 14, 21, 42 of IL-2 therapy, and on days 14 and 28 of the rest-period. IL-2 induced a rapid and evident decrease in cholesterol levels, with a normalisation of its concentrations within 7 days in 10/10 hypercholesterolemic patients. The lowest mean levels of cholesterol were reached within the first 2 weeks; after that they still slowly increased. LDL-/HDL-cholesterol ratio was significantly reduced by IL-2 therapy. Cholesterol fall was associated with a marked increase in conjugated biliary acid levels. Finally, triglyceride values increased during IL-2 therapy, but not in a significant manner. These results, by showing that IL-2 exerts an evident and very rapid cholesterol-lowering activity, would represent a further demonstration of the physiological importance of cytokines in the control of cholesterol metabolism.
The administration of interleukin-2 (IL-2) in the immunotherapy of cancer may induce important cardiovascular complications, including a severe hypotension, an increased capillary permeability, and cardiac ischaemic disorders (Rosenberg et al., 1987; Lee et al., 1989) . These side-effects are less evident when IL-2 is subcutaneously given (Atzpodien et al., 1990) . Hepatic, renal and haematological toxicities have been also observed during IL-2 immunotherapy (Rosenberg et al., 1987) . Moreover IL-2, as well as other cytokines, in addition to its immunomodulating properties, may also induce important endocrine and metabolic effects (Denicoff et al., 1989; Chambrier et al., 1990) . Among the metabolic effects of cytokines, granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to reduce cholesterol levels (Nimer et al., 1988) . Moreover, tumour necrosis factor (TNF) has appeared to cause hypertriglyceridemia (Sherman et al., 1988 Cholesterol and triglyceride serum levels were measured with a colorimetric method, by using commercial kits (PoliIndustria Chimica, Milan-Italy). HDL-and LDL-cholesterol levels were also determined with a colorimetric method, after lipoprotein precipitation with phosphotungstic acid and magnesium chloride by using commercial kits (Behring, Germany). Finally, serum levels of conjugated biliary acids were measured by RIA, by using commercially available kits (Becton-Dickinson, Orangeburg, NY Figure 1) . Finally the mean levels of conjugated biliary acids significantly increased in response to IL-2 injection, with a peak on day 3 (before: 4.2 ± 0.9 limol 1-l; after: 15.2 ± 2.5 ltmol l-l; P<0.005).
Discussion
The results of this study show that the subcutaneous administration of low-dose IL-2 is able to normalise cholesterol levels in hypercholesterolemic cancer patients. Therefore, this study confirms also with low-dose IL-2 subcutaneous therapy the results previously described by other authors (Wilson et al., 1989) with very high doses of IL-2 given intravenously. The IL-2 cholesterol-lowering activity seems to be more rapid and pronounced than that of 3-hydroxyl-3-methylglutarilcoenzyme A (HMG-CoA) reductase inhibitors (Tobert, 1987) , and comparable to that observed with GM-CSF (Nimer et al., 1988) . HDL-and LDL-cholesterol cholesterol levels during IL-2 therapy is associated with an increase in triglyceride concentrations. The IL-2-induced TNF rise (Nedwin et al., 1985) would explain triglyceride increase, but not the fall in cholesterol, which does not seem to be influenced by TNF (Sherman et al., 1988) . Moreover, at present it is unknown whether IL-2 per se may be responsible for cholesterol-lowering activity, or whether this effect may depend on other cytokines produced in response to IL-2, particularly GM-CSF itself, which secretion is stimulated by IL-2 (Michalevicz et al., 1988) . The evidence of a concomitant decrease in HLD-and LDL-cholesterol would suggest an inhibition of cholesterol synthesis, whereas we can exclude that cholesterol fall may be simply due to changes in body weight or in the dietary regimen, since no patient showed important nausea, anorexia or body weight variations during IL-2 therapy. The decline in cholesterol synthesis could be due to a direct inhibition of HMG-CoA reductase, or to a stimulation of LDL and scavenger macrophage receptors, which play a main role in the removal of cholesterol and in the formation of foam cells (Goldstein et al., 1979) . In fact, activated T lymphocyte products, which contain IL-2, have been shown either to inhibit HMG-CoA reductase activity (Fogelman et al., 1982) , or to modulate LDL macrophage receptor expression (Fogelman et al., 1983) . Therefore, we cannot exclude a direct action of IL-2 on hepatic macrophages, which express IL-2 receptors (Malkovsky & Sondel, 1987) and release factors acting on cholesterol metabolism (Cai et al., 1988) . However, the IL-2-induced hepatic function damage, as documented by the increase in transaminases and in gamma-GT, could also play a role in determining a reduced cholesterol synthesis, whereas .11^%-other factors, including leukocyte proliferation (Rosenberg et al., 1987) and cortisol rise (Denicoff et al., 1989) induced by IL-2, would not be enough to explain the rapid and very pronounced fall in cholesterol levels, which occurs within few days from the start of IL-2 therapy, and precedes leukocyte proliferation. The progressive decline with time in IL-2 cholesterollowering activity, observed in this study despite the continuous IL-2 injection and not shown by Wilson et al. (1989) with a shorter period of administration, might depend on a possible down-regulation of IL-2 macrophage receptors, determined by the prolonged administration of IL-2. The difference between our results and those referred by Wilson et al. (1989) , who described a more rapid return to baseline values with IL-2 interruption, could be due to differences in doses, route and schedule of IL-2 therapy.
The evidence that IL-2 affects cholesterol metabolism would suggest a possible role of IL-2, which endogenous availability decreases with age (Saadeh et al., 1986) , in the pathogenesis of atherosclerosis, as recently proposed for other cytokines (Ross, 1986) . If future studies will confirm also in non-oncologic hypercholesterolemic patients its cholesterol-lowering activity, clinical trials will be justified to investigate the possible use of IL-2 in the treatment of cholesterol metabolism disorders.
